Medicago is a leading clinical-stage biopharmaceutical company using disruptive plant-based and virus-like particle (VLP) technologies to rapidly develop innovative vaccines and therapeutic proteins for infectious diseases and emerging public health challenges. Medicago’s technologies represent a game-changing approach to vaccine development and disease response. Unlike traditional pharmaceutical manufacturing, Medicago’s plant-based platform can more rapidly produce safe and effective vaccines and antibodies while also potentially providing broader and more sustained protection.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.